Dr. Tania Gonzalez-Rivera, MD, BENLYSTA Global Medical Affairs Lead at GlaxoSmithKline (GSK) discusses the recent FDA approval of BENLYSTA (Belimumab) the first and only approved biologic treatment for both lupus and adult patients with active lupus nephritis who are receiving standard therapy. This approval builds on 10 years of clinical evidence.
Tania C. González-Rivera, MD, BENLYSTA Global Medical Affairs Lead at GlaxoSmithKline (GSK), has a deep breadth of experience in Medical Affairs spanning a variety of therapeutic areas. As a board-certified rheumatologist with clinical expertise in systemic lupus erythematosus (SLE) and other complex autoimmune diseases, she also has extensive knowledge regarding clinical trials and a background in translational research for SLE and lupus nephritis (LN). Dr. González-Rivera earned her Doctor in Medicine and completed her Residency in Internal Medicine at the University of Puerto Rico School of Medicine, and completed her Rheumatology Fellowship at the University of Michigan.